Exciting times indeed. Intellectual property
Post# of 30070
Posted On: 08/12/2014 12:29:44 AM
Exciting times indeed.
Intellectual property is the key to the vault at Big Pharma or any other Major player that wants to become your partner in one or many projects in the pipeline at AMBS.
I liked this little nugget from todays news.
"We are extremely pleased to be adding the Buck Institute for Research on Aging to our expanding consortium of leading academic research institutions focused on furthering the scientific understanding of MANF and its implications for therapeutic development," said Gerald E. Commissiong, President & CEO of Amarantus. "We were highly impressed with preliminary data generated at the Buck Institute. Given the stellar science from the Jasper and Lamba labs, we are confident that this will be just the beginning of our relationship with the Buck. As we continue our strategy of attracting all relevant MANF intellectual property into the Company on our path towards first-in-man human clinical studies, this agreement greatly adds to our war chest of MANF intellectual property and opens the door to significantly increasing our understanding of this therapeutically relevant, evolutionally conserved protein ."
http://finance.yahoo.com/news/amarantus-enter...rc=applewf
Not a stretch to think this time next year, shareholders of record will own 2 stocks that trade on a national exchange. It all depends on the science and IP.
Intellectual property is the key to the vault at Big Pharma or any other Major player that wants to become your partner in one or many projects in the pipeline at AMBS.
I liked this little nugget from todays news.
"We are extremely pleased to be adding the Buck Institute for Research on Aging to our expanding consortium of leading academic research institutions focused on furthering the scientific understanding of MANF and its implications for therapeutic development," said Gerald E. Commissiong, President & CEO of Amarantus. "We were highly impressed with preliminary data generated at the Buck Institute. Given the stellar science from the Jasper and Lamba labs, we are confident that this will be just the beginning of our relationship with the Buck. As we continue our strategy of attracting all relevant MANF intellectual property into the Company on our path towards first-in-man human clinical studies, this agreement greatly adds to our war chest of MANF intellectual property and opens the door to significantly increasing our understanding of this therapeutically relevant, evolutionally conserved protein ."
http://finance.yahoo.com/news/amarantus-enter...rc=applewf
Not a stretch to think this time next year, shareholders of record will own 2 stocks that trade on a national exchange. It all depends on the science and IP.
(0)
(0)